(Q40548309)

English

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

scientific article published on 8 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

phase III clinical trial

0 references

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Josep M. Llovet

20

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Vincenzo Mazzaferro

object named as

Vincenzo Mazzaferro

3

0 references

14

object named as

Luigi Bolondi

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

13

object named as

Sasan Roayaie

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

9

object named as

Kwang-Hyub Han

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

10

object named as

Won Young Tak

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

4

object named as

Gar-Yang Chau

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Gerold Meinhardt

19

object named as

Gerold Meinhardt

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

12

object named as

Tianqiang Song

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

11

object named as

Han Chu Lee

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Tadatoshi Takayama

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Jiamei Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Jianqiang Cai

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Ronnie T Poon

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Kwan Sik Lee

15

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Masatoshi Makuuchi

16

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Fabricio Souza

17

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Marie-Aude Le Berre

18

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

STORM investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

8 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1344-1354

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors of hepatocellular carcinoma--current status and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent advances in the prevention of hepatocellular carcinoma recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver cancer: Approaching a personalized care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma: clinical frontiers and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Resection and liver transplantation for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of antiviral treatment for HCC prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Refining sorafenib therapy: lessons from clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900198-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00198-9

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

release_v2o6uzax2zaatmwqknlu7e7gmu

1 reference

https://api.fatcat.wiki/v0/release/v2o6uzax2zaatmwqknlu7e7gmu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40548309&oldid=1900253684"